The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
The CCL20-CCR6 Axis in Cancer Progression
Open accessAbstract
Chemokines, which are basic proteins that exert their effects via G protein-coupled receptors and a subset of the cytokine family, are mediators deeply involved in leukocyte migration during an inflammatory reaction. Chemokine (C-C motif) ligand 20 (CCL20), also known as macrophage inflammatory protein (MIP)-3α, liver activation regulated chemokine (LARC), and Exodus-1, is a small protein that is physiologically expressed in the liver, colon, and skin, is involved in tissue inflammation and homeostasis, and has a specific receptor C-C chemokine receptor 6 (CCR6). The CCL20-CCR6 axis has long been known to be involved in inflammatory and infectious diseases, such as rheumatoid arthritis and human immunodeficiency virus infections. Recently, however, reports have shown that the CCL20-CCR6 axis is associated with several cancers, including hepatocellular carcinoma, colorectal cancer, breast cancer, pancreatic cancer, cervical cancer, and kidney cancer. The CCL20-CCR6 axis promotes cancer progression directly by enhancing migration and proliferation of cancer cells and indirectly by remodeling the tumor microenvironment through immune cell control. The present article reviewed the role of the CCL20-CCR6 axis in cancer progression and its potential as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
lncRNA‑u50535 promotes the progression of lung cancer by activating CCL20/ERK signaling
Wei, W., Zhao, X., Zhu, J., Zhang, L., Chen, Y., Zhang, B., Li, Y., Wang, M., Zhang, Z., & Wang, C. (2019) · Oncology Reports · doi:10.3892/or.2019.7302 · Cited by 23
RetractedSiegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
Regulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · cited 1×
“In recent years, however, immune checkpoint inhibitors had become the prominent treatment method for RCC, with immune tolerance again becoming the main concern in the treatment of RCC [68].”
BackgroundAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“However, cytokines have been found to be significantly upregulated in many cancers, promoting cancer growth and progression within the tumor microenvironment (TME) [1,2].”
BackgroundPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nagarsheth, N., Wicha, M. S., & Zou, W. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.49 · Cited by 2,206
Davies, L. C., Jenkins, S. J., Allen, J. E., & Taylor, P. R. (2013) · Nature Immunology · doi:10.1038/ni.2705 · Cited by 2,096
From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation
Italiani, P., & Boraschi, D. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00514 · Cited by 2,067
Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and Immunity
Griffith, J. W., Sokol, C. L., & Luster, A. D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120145 · Cited by 2,059
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Phenotypic and functional features of human Th17 cells
Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Filì, L., Ferri, S., Frosali, F., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070663 · Cited by 1,861
Surface phenotype and antigenic specificity of human interleukin 17–producing T helper memory cells
Acosta-Rodriguez, E. V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., & Napolitani, G. (2007) · Nature Immunology · doi:10.1038/ni1467 · Cited by 1,828
Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399 · cited 1×
“Tumor immunity is deeply involved in the development of melanoma, considering that immune checkpoint inhibitors—nivolumab and ipilimumab—have been shown to be effective [81].”
BackgroundThe Chemokine Superfamily Revisited
Zlotnik, A., & Yoshie, O. (2012) · Immunity · doi:10.1016/j.immuni.2012.05.008 · Cited by 1,235
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Tosolini, M., Kirilovsky, A., Mlecnik, B., Fredriksen, T., Mauger, S., Bindea, G., Berger, A., Bruneval, P., Fridman, W.-H., Pagès, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2907 · Cited by 1,146
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
The Terminology Issue for Myeloid-Derived Suppressor Cells
Gabrilovich, D. I., Bronte, V., Chen, S.-H., Colombo, M. P., Ochoa, A., Ostrand-Rosenberg, S., & Schreiber, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3037 · Cited by 835
Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis
Rowe, J., Ghouri, Y., & Mian, I. (2017) · Journal of Carcinogenesis · doi:10.4103/jcar.jcar_9_16 · Cited by 719
The growing role of precision and personalized medicine for cancer treatment
Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., et al. (2018) · TECHNOLOGY · doi:10.1142/s2339547818300020 · Cited by 698
Origins of tumor-associated macrophages and neutrophils
Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 689
The mononuclear phagocyte system
Hume, D. A. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.11.008 · Cited by 649
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Breast cancer stem cells, cytokine networks, and the tumor microenvironment
Korkaya, H., Liu, S., & Wicha, M. S. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57099 · Cited by 616
Cancer related inflammation: the macrophage connection
Sica, A., Allavena, P., & Mantovani, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.028 · Cited by 601
CCR6 Regulates the Migration of Inflammatory and Regulatory T Cells
Yamazaki, T., Yang, X. O., Chung, Y., Fukunaga, A., Nurieva, R., Pappu, B., Martin-Orozco, N., Kang, H. S., Ma, L., Panopoulos, A. D., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8391 · Cited by 551
Bell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544 · cited 1×
“However, cytokines have been found to be significantly upregulated in many cancers, promoting cancer growth and progression within the tumor microenvironment (TME) [1,2].”
BackgroundZhang, J.-P., Yan, J., Xu, J., Pang, X.-H., Chen, M.-S., Li, L., Wu, C., Li, S.-P., & Zheng, L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.033 · Cited by 535
Cook, D. N., Prosser, D. M., Forster, R., Zhang, J., Kuklin, N. A., Abbondanzo, S. J., Niu, X.-D., Chen, S.-C., Manfra, D. J., Wiekowski, M. T., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80201-0 · Cited by 498
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
Sfanos, K. S., Bruno, T. C., Maris, C. H., Xu, L., Thoburn, C. J., DeMarzo, A. M., Meeker, A. K., Isaacs, W. B., & Drake, C. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5164 · Cited by 427
Poon, D., Anderson, B. O., Chen, L.-T., Tanaka, K., Lau, W. Y., Van Cutsem, E., Singh, H., Chow, W. C., Ooi, L. L., Chow, P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70241-4 · Cited by 410
Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC
Baba, M., Imai, T., Nishimura, M., Kakizaki, M., Takagi, S., Hieshima, K., Nomiyama, H., & Yoshie, O. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.23.14893 · Cited by 409
Chun, E., Lavoie, S., Michaud, M., Gallini, C. A., Kim, J., Soucy, G., Odze, R., Glickman, J. N., & Garrett, W. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.024 · Cited by 402
Hieshima, K., Imai, T., Opdenakker, G., Van Damme, J., Kusuda, J., Tei, H., Sakaki, Y., Takatsuki, K., Miura, R., Yoshie, O., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5846 · Cited by 358
CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers
Huang, B., Lei, Z., Zhao, J., Gong, W., Liu, J., Chen, Z., Liu, Y., Li, D., Yuan, Y., Zhang, G.-M., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.012 · Cited by 349
Tumor microenvironments direct the recruitment and expansion of human Th17 cells
Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., & Peng, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902813 · Cited by 324
Power, C. A., Church, D. J., Meyer, A., Alouani, S., Proudfoot, A. E. I., Clark-Lewis, I., Sozzani, S., Mantovani, A., & Wells, T. N. C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.6.825 · Cited by 282
Izumi, K., Fang, L., Mizokami, A., Namiki, M., Li, L., Lin, W., & Chang, C. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202367 · Cited by 247
Self-citationLiu, J., Zhang, N., Li, Q., Zhang, W., Ke, F., Leng, Q., Wang, H., Chen, J., & Wang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019495 · Cited by 245
Loberg, R. D., Ying, C., Craig, M., Yan, L., Snyder, L. A., & Pienta, K. J. (2007) · Neoplasia · doi:10.1593/neo.07307 · Cited by 242
Chen, K.-J., Lin, S.-Z., Zhou, L., Xie, H.-Y., Zhou, W.-H., Taki-Eldin, A., & Zheng, S.-S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024671 · Cited by 240
Wang, D., Yang, L., Yu, W., Wu, Q., Lian, J., Li, F., Liu, S., Li, A., He, Z., Liu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0701-2 · Cited by 234
Chen, P., Huang, Y., Bong, R., Ding, Y., Song, N., Wang, X., Song, X., & Luo, Y. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1354 · Cited by 227
Griffiths, R. W., Elkord, E., Gilham, D. E., Ramani, V., Clarke, N., Stern, P. L., & Hawkins, R. E. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0318-z · Cited by 200
Najjar, Y. G., Rayman, P., Jia, X., Pavicic, P. G., Rini, B. I., Tannenbaum, C., Ko, J., Haywood, S., Cohen, P., Hamilton, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1823 · Cited by 194
Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer
Amicarella, F., Muraro, M. G., Hirt, C., Cremonesi, E., Padovan, E., Mele, V, Governa, V, Han, J., Huber, X., Droeser, R. A., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310016 · Cited by 189 · cited 1×
“In a large CRC cohort, tumor-infiltrating IL17-producing cells have not worsened clinical outcome and recruit highly cytotoxic CCR5+CCR6+CD8+ T cells via the release of CCL5 and CCL20 [96].”
BackgroundChemokines and Chemokine Receptors: Orchestrating Tumor Metastasization
Marcuzzi, E., Angioni, R., Molon, B., & Calì, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010096 · Cited by 173
Cloning and characterization of exodus, a novel beta-chemokine.
Hromas, R., Gray, P. W., Chantry, D., Godiska, R., Krathwohl, M. D., Fife, K. H., Bell, G. I., Takeda, J., Aronica, S. M., Gordon, M. S., et al. (1997) · PubMed · doi:10.1182/blood.v89.9.3315 · Cited by 172
CCR6 and CCL20: Partners in Intestinal Immunity and Lymphorganogenesis
WILLIAMS, I. R. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1326.036 · Cited by 167
Wu, Y., Li, Y.-Y., Matsushima, K., Baba, T., & Mukaida, N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6384 · Cited by 166
Scapini, P., Laudanna, C., Pinardi, C., Allavena, P., Mantovani, A., Sozzani, S., & Cassatella, M. A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200107)31:7<1981::aid-immu1981>3.0.co;2-x · Cited by 159
Walch‐Rückheim, B., Mavrova, R., Henning, M., Vicinus, B., Kim, Y.-J., Bohle, R. M., Juhasz‐Böss, I., Solomayer, E., & Smola, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0732 · Cited by 143
Pavel, A. B., Song, T., Kim, H. J., DUCA, E. D., Krueger, J. G., Dubin, C., Peng, X., Xu, H., Zhang, N., Estrada, Y. D., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.07.013 · Cited by 142
Cheng, X., Li, Y., Tan, J. Y., Sun, B., Xiao, Y., Fang, X.-B., Zhang, X., Li, Q., Dong, J., Li, M., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.03.008 · Cited by 138
Chemokines and chemokine receptors: A new strategy for breast cancer therapy
Liu, H., Yang, Z., Lü, W., Chen, Z., Chen, L., Han, S., Wu, X. Y., Cai, T., & Cai, Y. (2020) · Cancer Medicine · doi:10.1002/cam4.3014 · Cited by 116
Cisplatin-stimulated macrophages promote ovarian cancer migration via the CCL20-CCR6 axis
Liu, W., Wang, W., Wang, X., Xu, C., Zhang, N., & Di, W. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.024 · Cited by 113
Oldham, K. A., Parsonage, G., Bhatt, R. I., Wallace, D. M. A., Deshmukh, N., Chaudhri, S., Adams, D. H., & Lee, S. P. (2012) · European Urology · doi:10.1016/j.eururo.2011.10.035 · Cited by 104
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
Berlato, C., Khan, M. N., Schioppa, T., Thompson, R. D., Maniati, E., Montfort, A., Jangani, M., Canosa, M., Kulbe, H., Hagemann, U. B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci82976 · Cited by 104
CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer
Chen, W., Qin, Y., Wang, D., Zhou, L., Liu, Y., Chen, S., Yin, L., Xiao, Y., Yao, X.-H., Yang, X., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005869 · Cited by 101
Tobacco smoke induces production of chemokine CCL20 to promote lung cancer
Wang, G., Cheng, X., Li, X., Liu, Y., Wang, X.-Q., Shi, X., Wang, Z.-Y., Guo, Y., Wen, Z., Huang, Y., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.005 · Cited by 94
The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology
Lee, A. Y. S., & Körner, H. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.01.005 · Cited by 91
Bacigalupo, M. L., Manzi, M., Rabinovich, G. A., & Troncoso, M. F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i47.8831 · Cited by 89
Nandi, B., Shapiro, M., Samur, M., Pai, C., Frank, N. Y., Yoon, C. H., PRABHALA, R. H., Munshi, N. C., & Gold, J. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1189052 · Cited by 87
Advances in pancreatic cancer research: Moving towards early detection
He, X., & Yuan, Y.-Z. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11241 · Cited by 82
Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer
Liu, B., Jia, Y., Ma, J., Wu, S., Jiang, H., Cao, Y., Sun, X., Yin, X. L., Yan, S., Shang, M., et al. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw101 · Cited by 81
Rucki, A. A., Foley, K., Zhang, P., Xiao, Q., Kleponis, J., Wu, A. A., Sharma, R. B., Mo, G., Liu, A., Eyk, J. E. V., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1383 · Cited by 80
Interaction between CXCR4 and CCL20 Pathways Regulates Tumor Growth
Beider, K., Abraham, M., Begin, M., Wald, H., Weiss, I. D., Wald, O., Pikarsky, E., Abramovitch, R., Zeira, E., Galun, E., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005125 · Cited by 75
Chemokines and hepatocellular carcinoma
Huang, F. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i15.1832 · Cited by 72
Chemokines in Inflammatory Bowel Diseases
Atreya, R. N., & Neurath, M. (2010) · Digestive Diseases · doi:10.1159/000320392 · Cited by 72
Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis
Lee, S., Park, K.-K., Kim, H., Park, J., Son, S. H., Kim, K., & Chung, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-09040-4 · Cited by 72
Preferential Recruitment of Th17 Cells to Cervical Cancer via CCR6-CCL20 Pathway
Yu, Q., Lou, X., & He, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120855 · Cited by 71
A tumour‐promoting role of Th9 cells in hepatocellular carcinoma through CCL20 and STAT3 pathways
Tan, H., Wang, S., & Zhao, L. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12689 · Cited by 71
mTORC2 mediates CXCL12-induced angiogenesis
Ziegler, M. E., Hatch, M. M. S., Wu, N., Muawad, S. A., & Hughes, C. C. W. (2016) · Angiogenesis · doi:10.1007/s10456-016-9509-6 · Cited by 69
Functional expression of chemokine receptor CCR6 on human effector memory CD8 + T cells
Kondo, T., Takata, H., & Takiguchi, M. (2006) · European Journal of Immunology · doi:10.1002/eji.200636251 · Cited by 66
CCL 2 as a potential therapeutic target for clear cell renal cell carcinoma
Arakaki, R., Yamasaki, T., Kanno, T., Shibasaki, N., Sakamoto, H., Utsunomiya, N., Sumiyoshi, T., Shibuya, S., Tsuruyama, T., Nakamura, E., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.886 · Cited by 65
Kadomoto, S., Izumi, K., Hiratsuka, K., Nakano, T., Naito, R., Makino, T., Iwamoto, H., Yaegashi, H., Shigehara, K., Kadono, Y., et al. (2019) · Cancers · doi:10.3390/cancers12010089 · Cited by 61
Self-citationIL-17 Secreted by Tumor Reactive T Cells Induces IL-8 Release by Human Renal Cancer Cells
Inozume, T., Hanada, K., Wang, Q. J., & Yang, J. C.-H. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819302da · Cited by 56
CrkL meditates CCL20/CCR6-induced EMT in gastric cancer
Han, G., Wu, D., Yang, Y.-A., Li, Z., Zhang, J., & Li, C. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.009 · Cited by 54
Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinoma
Zhang, X., Hu, Z., Meng, A., Duan, G., Zhao, Q., & Yang, J. H. (2017) · Oncology Letters · doi:10.3892/ol.2017.7253 · Cited by 54
Kapur, N., Mir, H., Clark, C. E., Krishnamurti, U., Beech, D. J., Lillard, J. W., & Singh, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.113 · Cited by 53
CCR6, the Sole Receptor for the Chemokine CCL20, Promotes Spontaneous Intestinal Tumorigenesis
Nandi, B., Pai, C., Huang, Q. M., PRABHALA, R. H., Munshi, N. C., & Gold, J. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097566 · Cited by 52
Geismann, C., Grohmann, F., Dreher, A., Häsler, R., Rosenstiel, P. C., Legler, K., Hauser, C., Egberts, J. H., Sipos, B., Schreiber, S., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.02.005 · Cited by 52
Skewed T-helper (Th)1/2- and Th17/T regulatory-cell balances in patients with renal cell carcinoma
LI, L., Yang, C., Zhao, Z., Xu, B., Zheng, M., Zhang, C., Min, Z., Guo, J., & Rong, R. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2778 · Cited by 51
He, H., Wu, J., Zang, M., Wang, W., Chang, X., Chen, X., Wang, R., Wu, Z., Wang, L., Wang, D., et al. (2017) · Europe PMC (PubMed Central) · Cited by 48
Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer
Ghadjar, P., Loddenkemper, C., Coupland, S. E., Stroux, A., Noutsias, M., Thiel, E., Christoph, F., Miller, K., Scheibenbogen, C., & Keilholz, U. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0403-5 · Cited by 47
Bouma, G., Zamuner, S., Hicks, K. J., Want, A., de Oliveira, J. J., Choudhury, A., Brett, S. J., Robertson, D. C., Felton, L. M., Norris, V., et al. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13286 · Cited by 47
Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
Middel, P., Brauneck, S., Meyer, W., & Radzun, H. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-578 · Cited by 43
Chen, D., Jiang, R., Mao, C., Shi, L., Wang, S., Yu, L., Hu, Q., Dai, D., & Xu, H. (2012) · Human Immunology · doi:10.1016/j.humimm.2012.07.333 · Cited by 43
Wang, Z., Xie, H., Zhou, L., Liu, Z., Fu, H., Zhu, Y., Xu, L., & Xu, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10492 · Cited by 43
Wang, D., Yuan, W., Wang, Y., Wu, Q., Yang, L., Li, F., Chen, X., Zhang, Z., Yu, W., Maimela, N. R., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2008-y · Cited by 43
Corrò, C., Healy, M. E., Engler, S., Bodenmiller, B., Li, Z., Schraml, P., Weber, A., Frew, I. J., Rechsteiner, M., & Moch, H. (2019) · The Journal of Pathology · doi:10.1002/path.5267 · Cited by 42
Kaneko, S., Kondo, Y., Yokosawa, M., Furuyama, K., Segawa, S., Tsuboi, H., Kanamori, A., Matsumoto, I., Yamazaki, M., & Sumida, T. (2017) · Modern Rheumatology · doi:10.1080/14397595.2017.1416923 · Cited by 35
GUAN, X., Liu, Z., Zhang, J., & Jin, X. (2018) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/70065 · Cited by 34
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells
D’Amico, L., Belisario, D. C., Migliardi, G., Grange, C., Bussolati, B., D’Amelio, P., Perera, T. P. S., Dalmasso, E., Carbonare, L. D., Godio, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9997 · Cited by 31
A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6
Robert, R., Juglair, L., Lim, E. X., Ang, C., Wang, C. J. H., Ebert, G., Dolezal, O., & Mackay, C. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184278 · Cited by 25
Schüler, Y., Lee‐Thedieck, C., Geiger, K., Kaiser, T., Ino, Y., Aicher, W. K., & Klein, G. (2011) · International Journal of Cancer · doi:10.1002/ijc.25981 · Cited by 24
Xiao, W., Jia, Z., Zhang, Q., Wei, C., Wang, H., & Wu, Y. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3800 · Cited by 23
Saito, M., Sejima, H., Naito, T., Ushirogawa, H., Matsuzaki, T., Matsuura, E., Tanaka, Y., Nakamura, T., & Takashima, H. (2017) · Virology Journal · doi:10.1186/s12985-017-0902-6 · Cited by 15
Cited by
Macrophage Polarity and Disease Control
Kadomoto, S., Izumi, K., & Mizokami, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010144 · Cited by 318
Self-citationXu, C., Fan, L., Lin, Y., Shen, W., Qi, Y., Zhang, Y., Chen, Z., Wang, L., Long, Y., Hou, T., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1980347 · Cited by 289
Metadata
- Authors
- Kadomoto, S., Izumi, K., & Mizokami, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-22
- Volume
- 21
- Issue
- 15
- Pages
- 5186
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3043853060
- Cited by
- 267
- References
- 107
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.